Position in NSRX
as of Mar 31, 2026
· filed May 5, 2026
Position Value
$6,868
+$3,410 QoQ
Shares Held
3,094
+718.5% QoQ
Ownership
0.026%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#8
of 9 holders
Holding Since
Sep 2025
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NSRX Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Mar 31, 2026UBS Group AG holds $15,459,459,109 across 21 Drug Manufacturers - General names. NSRX ranks #21 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
4,043,568 | $3,719,152,536 | |
| 2 | ABBV |
AbbVie Inc.
|
14,051,196 | $3,055,994,614 | |
| 3 | JNJ |
Johnson & Johnson
|
10,209,327 | $2,495,567,886 | |
| 4 | MRK |
Merck & Co., Inc.
|
13,933,630 | $1,676,076,347 | |
| 5 | AZN |
Astrazeneca PLC
|
5,981,411 | $1,179,653,872 | |
| 6 | AMGN |
Amgen Inc
|
3,148,040 | $1,107,637,870 | |
| 7 | GILD |
Gilead Sciences, Inc.
|
3,930,216 | $547,754,202 | |
| 8 | PFE |
Pfizer Inc
|
17,609,150 | $494,464,929 |
All Filings in NSRX
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $6,868 | 3,094 | Shares | Defined | 2026-05-05 | |
| 2025-12-31 | $3,458 | 378 | Shares | Defined | 2026-01-29 | |
| 2025-09-30 | $8,252 | 1,241 | Shares | Defined | 2025-11-13 | |
| No filing history on record for this holder in this stock. | ||||||